Navigation Links
Cambrex Reports Third Quarter 2008 Results
Date:11/4/2008

and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation or regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and the accuracy of the Company's current estimates with respect to its earnings and profits for tax purposes in 2007. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time and it is not possible for the Company to predict which new factors will arise. In addition, we cannot assess the impact of each factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors and security holders are cautioned to review the Cambrex 2007 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other subsequent filings with the U.S. Securities and Exchange Commission, including Current Reports on Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future ev
'/>"/>

SOURCE Cambrex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 The ... committed to lowering the barriers to innovation in ... the appointment of Carmen Nitsche as Executive Director ... to expand its global reach. , Carmen joins ... Vice President, Corporate Development. At Accelrys, she managed ...
(Date:9/16/2014)... , Sept. 16, 2014 This report analyzes ... following Product Segments: Software, Hardware, and Biocontent. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
(Date:9/16/2014)... --The emerging field of molecular electronics could take ... enabling the construction of tiny circuits from molecular ... would take on the roles currently played by ... of researchers from five Japanese and Taiwanese universities ... small-scale electronics: a molecule called picene. In a ...
(Date:9/16/2014)... 16, 2014 BlueInGreen® , ... efficient method for delivering dissolved gases into liquids, ... as a manufacturer’s representative firm to its ... products for municipal water and wastewater applications in ... H2Flow was founded in 1992 and serves Quebec ...
Breaking Biology Technology:Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23The future face of molecular electronics 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2
... , , , , , ... that can be applied to all PCR amplifications. For example, , ... of the PCRs can differ from each other. Finding the optimal ... for reliable results , and efficient amplification of a specific ...
... , , , , , , ... University Hospital and Medical School of the Dutch-speaking Brussels Free , ... , , , , , ... , Preimplantation diagnosis (PGD) is a very early form ...
... , , , , ... Behrens, PhD, and Dietmar Kahle, PhD , ... Dept., Bernhard-Nocht-Str. 74, D-20359 Hamburg , ... Am Botanischen Garten, D-24118 Kiel , Barbara ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 2The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 3The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 4The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 5Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 2Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 3Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 4Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 5Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 6Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 7Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 8Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 9Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 10
(Date:9/16/2014)... American Menopause Society (NAMS) has published its key, ... womenon everything from hot flashes to heart disease. ... Recommendations for Clinical Care of Midlife Women," was ... Menopause . This is the first, comprehensive set ... women freely available to all clinicians who care ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
(Date:9/16/2014)... species has its own bacterial identity. That,s the conclusion ... institutions who studied the genetic fingerprints of bacteria on ... , "This study demonstrates for the first time that ... ecological strategies possess very different microbial communities on their ... postdoctoral researcher in the UO,s Institute of Ecology and ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2
... Motion, Matches with Watch-list Databases and Reports ... Neurotechnology, a provider of high-precision biometric ... VeriLook Surveillance SDK, a software development kit ... streams from high-resolution digital surveillance cameras. Unlike ...
... March 10 CEL-SCI Corporation (NYSE Alternext US: CVM) ... a new manufacturing process that could allow drugs developed ... their potency and thereby potentially also their shelf life. ... CEL-SCI may also significantly accelerate the time to market ...
... results March 19 during 12 p.m. Advertising Research ... Research (R), a revolutionary media research firm, recently ... Research Foundation (ARF) conference and provided attendees with ... that comprise impactful presentations. Results of the study, ...
Cached Biology News:VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 4Innerscope Research(R) Uses Same-Day Results From Biometric Study to Identify Key Themes, Styles Behind Effective, Engaging Speaker Presentations 2
... Human CELSR3 CELSR3 is an Orphan-U ... this gene is expressed during development at sites ... rats in brain, spinal cord, dorsal root ganglion, ... B-cell/lung/testis, blood, brain, colon, heart/melanocyte/uterus, lung, nerve, and ...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse Amphiregulin MAb (Clone 206220)...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
Biology Products: